Amid heightened public concern, the cost of prescription drugs is the focus of renewed attention by the Trump administration, the Biden campaign and lawmakers in Congress and state capitals. Proposed actions range from sweeping health care system changes to targeted initiatives that could affect Medicare, Medicaid and private insurance. See KFF’s research, analysis and public opinion data, as well as Kaiser Health News’ journalism, related to prescription drugs and their costs.
This poll examines health care issues in the Democratic presidential primary , government negotiation of prescription drug prices, party trust on health care, Medicare-for-all, and the pending Texas v. US lawsuit affecting the Affordable Care Act and pre-existing condition protections.
This slideshow explains the similarities and differences among major proposals to lower prescription drug costs introduced by the Trump Administration, members of Congress, and the Biden campaign.
No, Medicare Advantage plans charge the same premiums to all enrollees; they are not permitted to vary premiums based on age, smoking history, gender, or pre-existing medical conditions.FAQ Read More
If you enroll in a plan during the Medicare Open Enrollment period that runs from October 15 to December 7 each year, your coverage takes effect on January 1 of the following year.FAQ Read More
The Kaiser Family Foundation and the Health Research and Educational Trust have conducted this annual survey since 1999. The archives of the Employer Health Benefits Survey include these surveys and a small business supplement of the 1998 survey conducted by the Foundation. The survey was previously conducted by KPMG from…Report Read More
These FAQs provide background on prescription drug importation, including how the U.S. currently regulates importation and why it hasn’t been successfully implemented before. These FAQs also describe the newest importation proposals, both by the Trump Administration and at the state level, how these proposals seek to address concerns with prior proposals, and how stakeholders are viewing these newest proposalsIssue Brief Read More
The repeal of the ACA could mean loss of Medicaid coverage for up to 15 million that were enrolled in the ACA Medicaid expansion group prior to the COVID-19 pandemic; however, repeal could also mean significant changes to Medicaid prescription drug policy with implications for state and federal spending for prescription drugs for non-expansion Medicaid enrollees.Issue Brief Read More